Nanotechnology Now - Press Release: "OctoPlus publishes Annual Report 2008 and reiterates revised strategy for 2009"

Home > Press > OctoPlus publishes Annual Report 2008 and reiterates revised strategy for 2009

Abstract:
OctoPlus N.V. ("OctoPlus" or "the Company") (Euronext: OCTO) announces today the publication of its Annual Report 2008.

OctoPlus publishes Annual Report 2008 and reiterates revised strategy for 2009

The Netherlands | Posted on March 30th, 2009

During the year 2008, OctoPlus adapted its strategy to utilise its proprietary drug delivery technology for the controlled release of injectable products, in particular proteins, on behalf of a growing client base. The main product based on this technology, Locteron®, is moving into clinical Phase IIb this year. In 2008, OctoPlus worked on five projects to evaluate the feasibility of a controlled release formulation that combines the active ingredient of the client with OctoPlus' proprietary drug delivery technology, and the Company aims to sign six more in 2009. Together with the anticipated growth in our Contract Development services we expect to be able to achieve a positive cashflow at the operational level for the year 2009.

The Annual Report is available on the Company's website, www.octoplus.nl. Hard copies of the report can be requested by sending an e-mail to

Annual General Meeting of Shareholders
The Annual General Meeting of Shareholders (AGM) will take place at the Company's headquarters in Leiden on 23 April 2009 at 14:00 Central European Time (CET). The agenda and other information regarding the AGM will be published on 8 April 2009 via the Company's website.

For further information, please contact:
Rianne Roukema, Corporate Communications: telephone number +31 (71) 524 1071, e-mail

This document may contain certain forward-looking statements relating to the business, financial performance and results of OctoPlus and the industry in which it operates. These statements are based on OctoPlus' current plans, estimates and projections, as well as its expectations of external conditions and events. In particular the words "expect", "anticipate", "predict", "estimate", "project", "plan", "may", "should", "would", "will", "intend", "believe" and similar expressions are intended to identify forward-looking statements. We caution investors that a number of important factors, and the inherent risks and uncertainties that such statements involve, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements. In the event of any inconsistency between an English version and a Dutch version of this document, the English version will prevail over the Dutch version.

####

About OctoPlus
OctoPlus is a product-oriented biopharmaceutical company committed to the creation of improved pharmaceutical products that are based on OctoPlus' proprietary drug delivery technologies and have fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies. Rather than seeking to discover novel drug candidates through early stage research activities, OctoPlus focuses on the development of long-acting, controlled release versions of known protein therapeutics, other drugs, and vaccines on behalf of its clients.

The lead product incorporating our technology is Locteron®, a controlled release formulation of interferon alfa for the treatment of chronic hepatitis C, which has been licensed to Biolex Therapeutics and is being manufactured by OctoPlus. Locteron is currently in Phase II clinical studies.

In addition, OctoPlus is a leading European provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industries, with a focus on difficult-to-formulate active pharmaceutical ingredients.

OctoPlus is listed on Euronext Amsterdam by NYSE Euronext under the symbol OCTO. For more information about OctoPlus, please visit our website www.octoplus.nl.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: